Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.
Chmiel, Katarzyna D; Suan, Dan; Liddle, Christopher; Nankivell, Brian; Ibrahim, Ramy; Bautista, Charmaine; Thompson, John; Fulcher, David; Kefford, Richard.
J Clin Oncol
; 29(9): e237-40, 2011 Mar 20.
Artigo em Inglês | MEDLINE | ID: mdl-21220617
Loss of IFN-Î³ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL.
Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab.
Safety of shortened infusion times for combined ipilimumab and nivolumab.
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma.
Terapeutický efekt a tolerance ipilimumabu u metastatického maligního melanomu v detském veku -â kazuistika.
Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma.